Ys Biopharma Co Stock Fundamentals
YSDelisted Stock | 1.42 0.05 3.65% |
YS Biopharma Co fundamentals help investors to digest information that contributes to YS Biopharma's financial success or failures. It also enables traders to predict the movement of YS Biopharma Stock. The fundamental analysis module provides a way to measure YS Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to YS Biopharma stock.
YS Biopharma |
YS Biopharma Co Company Shares Outstanding Analysis
YS Biopharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current YS Biopharma Shares Outstanding | 188.33 M |
Most of YS Biopharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, YS Biopharma Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, YS Biopharma Co has 188.33 M of shares currently outstending. This is 4.32% higher than that of the Biotechnology sector and 76.25% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 67.07% higher than that of the company.
YS Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining YS Biopharma's current stock value. Our valuation model uses many indicators to compare YS Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across YS Biopharma competition to find correlations between indicators driving YS Biopharma's intrinsic value. More Info.YS Biopharma Co is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value YS Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.YS Biopharma Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses YS Biopharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of YS Biopharma could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics of similar companies.YS Biopharma is currently under evaluation in shares outstanding category among its peers.
YS Biopharma Fundamentals
Return On Equity | -0.78 | |||
Return On Asset | -0.1 | |||
Profit Margin | (0.67) % | |||
Operating Margin | (0.49) % | |||
Current Valuation | 430.4 M | |||
Shares Outstanding | 188.33 M | |||
Shares Owned By Insiders | 81.42 % | |||
Shares Owned By Institutions | 2.85 % | |||
Number Of Shares Shorted | 38.89 K | |||
Price To Book | 2.10 X | |||
Price To Sales | 0.29 X | |||
Revenue | 687.2 M | |||
EBITDA | (76.82 M) | |||
Net Income | (145.48 M) | |||
Total Debt | 498.63 M | |||
Book Value Per Share | 5.10 X | |||
Cash Flow From Operations | (182.47 M) | |||
Short Ratio | 0.31 X | |||
Earnings Per Share | (0.57) X | |||
Target Price | 4.25 | |||
Number Of Employees | 773 | |||
Beta | 0.54 | |||
Market Capitalization | 192.09 M | |||
Total Asset | 1.72 B | |||
Retained Earnings | (1.87 B) | |||
Working Capital | 377.22 M | |||
Net Asset | 1.72 B |
About YS Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze YS Biopharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of YS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of YS Biopharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |